share_log

爱朋医疗(300753.SZ):公司2023年度研发投入占营收比例为8.66%

Jiangsu Apon Medical Technology (300753.SZ): The company's R&D investment in 2023 accounts for 8.66% of its revenue.

Gelonghui Finance ·  Jul 19, 2024 06:10

Jiangsu Apon Medical Technology (300753.SZ) stated on the investor interaction platform on July 19 that the company has always attached great importance to R&D investment and planning since its listing, and continuously optimized its R&D organizational structure. The R&D investment ratio in 2023 accounted for 8.66% of the revenue, and has established a vertical product management system mainly based on core main business and a horizontal R&D organizational structure system supported by a product management platform and special technology. The company will gradually sort out the existing research and development products, focus on core technology areas, strengthen external industry-university-research strategic cooperation, and improve product development efficiency through strict product project management. By continuously optimizing and upgrading the main business products and building core technological strengths, the company strives for both stability and innovation.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment